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Summary
Primary immunodeficiencies (PID) are rare diseases; therefore transnational
studies are essential to maximize the scientific outcome and to improve diag-
nosis and therapy. In order to estimate the prevalence of PID in Europe as well
as to establish and evaluate harmonized guidelines for the diagnosis and
treatment of PID, the European Society for Immunodeficiencies (ESID) has
developed an internet-based database for clinical and research data on
patients with PID. This database is a platform for epidemiological analyses as
well as the development of new diagnostic and therapeutic strategies and the
identification of novel disease-associated genes.Within 4 years, 7430 patients
from 39 countries have been documented in the ESID database. Common
variable immunodeficiency (CVID) represents the most common entity, with
1540 patients or 20·7% of all entries, followed by isolated immunoglobulin
(Ig)G subclass deficiency (546 patients, 7·4%). Evaluations show that the
average life expectancy for PID patients varies from 1 to 49 years (median),
depending on the type of PID. The prevalence and incidence of PID remains
a key question to be answered.As the registration progress is far from finished
we can only calculate minimum values for PID, with e.g. France currently
showing a minimum prevalence of 3·72 patients per 100 000 inhabitants.
The most frequently documented permanent treatment is immunoglobulin
replacement; 2819 patients (42% of all patients alive) currently receive this
form of treatment.
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Primary immunodeficiencies (PID) are rare diseases caused
by inherited defects of the immune system. Advances in
medical research have led to the identification of more than
140 genes which cause more than 200 different forms of PID
[1].
Research on PID to date faces a range of difficulties. These
are due not only to the low prevalence, but also to the fact
that PID were discovered only half a century ago and are still
a somewhat new area for common medicine. In countries
such as Bulgaria, PID are even not acknowledged as disease
entities and therefore cannot be diagnosed and treated
accordingly.
In general, PID are under-diagnosed in most countries,
and many medical centres care for only few patients with
PID. This has made it extremely difficult to establish
sufficient data on the morbidity and mortality of PID.
Numerous surveys and registries have been set up to date to
answer questions on the epidemiology of PID, mainly by
national research networks [2–4]. Authors generally empha-
size that under-diagnosis and under-reporting as well as lack
of participation by hospitals produce shortcomings in the
results. These vary greatly, with incidence rates ranging from
1·4 to 10·1 in 100 000 live births [3,5]. The highest preva-
lence rate measured to date is 12·4 per 100 000 inhabitants in
South Australia [4].
It has been suggested that applying an incidence rate from
surveys in smaller regions with good documentation and a
centralized health-care system could be a way to estimate
incidence numbers for larger areas [5]. However, this
approach may not produce valid figures representative for
other regions. The prevalence of specific PID varies consid-
erably between ethnic groups [6], which implies that
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morbidity rates can vary greatly between regions, countries
and populations.
In addition to these evident difficulties in epidemiology,
the diversity of PID poses another challenge for researchers.
PID are caused by a large variety of genetic defects, and only
a proportion of these have been discovered to date. Some of
the known defects are extremely rare, which makes interna-
tional collaboration necessary to collect sufficient patient
numbers for adequate research. In 1994, European immu-
nologists formed a network of clinicians and researchers, the
European Society for Immunodeficiencies (ESID; http://
www.esid.org), to support research on the cause, mechanism
and therapy in immunodeficiencies.
Since 2004 ESID has been running a database for primary
immunodeficiencies, the results of which are presented here.
The ESID database is a secure, internet-based patient regis-
try, which combines both clinical and laboratory data of PID
patients. It provides a common data set for currently 214
different PID entities and is updated regularly, according to
progress in research. This core data set includes data on
diagnosis, therapy, laboratory data and health outcome
indicators.
With the database, ESID is striving to answer the challeng-
ing epidemiological questions outlined above. However,
unlike many other registries, it is not merely a single time-
point survey restricted to epidemiology; the ESID database
also serves as a research platform with long-term
documentation. Using the database, researchers have the
possibility to identify patient cohorts for genetic screening
and multi-centre trials. Data sets can be extended flexibly for
studies using the database as a platform for their reporting
forms.
A first analysis on the data collected from 2004 to 2006 has
been published in this journal [7]. Since then, the number of
registered cases has more than tripled, from 2386 to 7430.
Although this figure is still far from presenting a complete
picture of PID in Europe, the current results give valuable
insights into the epidemiology of PID, in particular in coun-
tries with a high documentation rate.
With the current results, we want to emphasize the enor-
mous potential of this database network, in particular for
conducting laboratory research and clinical trials, leading
finally to improvement of diagnosis, classification, prognosis
and therapy of primary immunodeficiency disorders.
Materials and methods
The system structure of the ESID online database has been
described by Perner et al. [7] and Guzman et al. [8].
Currently (December 2008) 76 documenting centres and
national registries from 30 countries have signed a contract
and obtained logins for the database system, which are nec-
essary to participate in the online documentation. Most
centres are located in Europe, but there are also centres in
Egypt and Iran, which show that the efforts of ESID go
beyond the geographical borders of Europe. Some of the
documenting centres co-ordinate national networks with
numerous subcentres, such as France and Italy. Therefore,
the actual total number of centres contributing patients to
the database is 158.
The ESID database for PID currently consists of 214
disease-specific registries, which are grouped within eight
main categories and 73 subcategories (see Table 1). The cat-
egorization is based on the latest classification established by
the International Union of Immunological Societies (IUIS)
in 2007 [9].
All disease-specific registries share a common core data
set. This core data set was designed to bring together basic
data for all PID patients in order to make general evaluations
possible. It contains information on diagnosis, therapy and
quality of life as well as the most important laboratory data
for PID [blood and lymphocyte count, immunoglobulin (Ig)
levels, complement values and data on important cell surface
markers]. The core data set has been extended recently by
fields asking for concomitant diseases and infectious epi-
sodes, as well as family history.
In addition to the core data, extended disease-specific data
sets have been implemented currently for 40 diseases, allow-
ing the documentation of an exhaustive set of parameters
that are relevant only for a specific PID, thus making more
detailed analyses possible.
Documentation and quality checks
The database is designed to be used for long-term
documentation. It offers the possibility to add any number of
visit dates for a given patient. Users are asked to update their
patients’ data at least once a year. On average, first-time data
entry takes 10–15 min per patient for the core data set,
depending on the availability of the patient data, and longer
if additional fields are documented. Regular updates take
considerably less time, usually less than 5 min per patient.
Some centres and national networks are maintaining pre-
existent local databases for their PID patients. Their data are
transferred electronically to the ESID system at regular
intervals.
The database has an inbuilt automatic quality assurance
system including field type, range and plausibility checks
(e.g. date of death must be greater than date of birth, blood
counts cannot sum to more than 100%). In addition, data
sets are checked regularly for plausibility and completeness
by the database administration.
Some fields are mandatory, which means that data cannot
be stored unless these fields are completed. However, many
fields are open to be completed, taking into account that the
data are sometimes not known or currently not available to
the documentalist. This explains why, in evaluations, the
number of evaluated cases does not always equal the total
number of registered cases in the database. Furthermore, the
database records both a patient’s country of residence as well
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Table 1. Distribution of cases registered in the European Society for Immunodeficiencies (ESID) online database by primary immunodeficiency (PID)
diseases. Some entities are subsumed under a common heading for layout reasons.
PID entity Total % of total
Predominantly antibody disorders 4073 54·82
Agammaglobulinaemias 518 6·97
X-linked (BTK) 436 5·87
Other known genetic defects 4 0·05
Genetic defect unknown 78 1·05
Hypogammaglobulinaemias 3326 44·76
Common variable immunodeficiency (CVID) 1540 20·73
Isolated immunoglobulin (Ig)G subclass deficiency 546 7·35
IgA deficiency 507 6·82
Transient hypogammaglobulinaemia of infancy 322 4·33
Deficiency of specific IgG 47 0·63
Selective IgM deficiency 49 0·66
Thymoma with immunodeficiency 19 0·26
Secondary hypogammaglobulinaemia 32 0·43
Secondary selective IgA deficiency 16 0·22
ICOS deficiency 6 0·08
CD19 antigen deficiency 3 0·04
Other hypogammaglobulinaemias 239 3·22
Class switch recombination defects/HIGM syndromes 229 3·08
CD40L deficiency/X-linked hyper-IgM 86 1·16
CD40 antigen deficiency 7 0·09
Other genetic defects 27 0·36
Genetic defect unknown 109 1·47
Predominantly T cell deficiencies 671 9·03
T–B+ severe combined immunodeficiency (SCID) 227 3·06
X-linked SCID 75 1·01
Janus kinase 3 deficiency (JAK3) 18 0·24
Interleukin 7 receptor deficiency (IL-7R) 10 0·13
Interleukin 2 receptor alpha deficiency (CD25) 6 0·08
Genetic defect unknown 118 1·59
T–B- severe combined immunodeficiency (SCID) 212 2·85
Recombination-activating gene deficiency (RAG1/2) 62 0·83
Adenosine deaminase deficiency (ADA) 42 0·57
DNA cross-link repair protein 1C deficiency (Artemis) 21 0·28
Reticular dysgenesia 3 0·04
Genetic defect unknown 84 1·13
HLA class II deficiency 57 0·77
MHC2TA deficiency 11 0·15
Other genetic defects 14 0·19
Genetic defect unknown 32 0·43
CD3 deficiency 10 0·13
Selective CD4 cell deficiency 39 0·52
Other genetic T cell defects 14 0·19
Other unclassified T cell disorders 112 1·51
Phagocytic disorders 932 12·54
Chronic granulomatous disease (CGD) 322 4·33
X-linked (CYBB) 182 2·45
AR cytochrome b positive type 1 (NCF1) 24 0·32
Other genetic defects 14 0·19
Genetic defect unknown 102 1·37
Severe congenital neutropenia (cyclic and non-cyclic) 209 2·81
Elastase 2 deficiency (ELA2) 9 0·12
Other genetic defects 5 0·07
Genetic defect unknown 195 2·62
Kostmann syndrome (HAX1) 78 1·05
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Table 1. Continued
PID entity Total % of total
Schwachman–Diamond syndrome 93 1·25
SBDS deficiency 7 0·09
Genetic defect unknown 86 1·16
Defects with susceptibility to mycobacterial infection 29 0·39
Interleukin 12 receptor beta-1 deficiency (IL-12RB1) 16 0·22
Other genetic defects 9 0·12
Genetic defect unknown 4 0·05
Familial haemophagocytic lymphohistiocytosis syndromes 89 1·20
Perforin 1 deficiency (PRF1) 14 0·19
Familial haemophagocytic lymphohistiocytosis 3 (UNC13D) 15 0·20
Genetic defect unknown 60 0·81
Griscelli syndrome 16 0·22
Leucocyte adhesion deficiency (LAD) 33 0·44
LAD type 1 (ITGB2) 28 0·38
LAD type 3 5 0·07
WHIM syndrome 15 0·20
Glucose-6-phosphate dehydrogenase deficiency (G6PD) 16 0·22
Chediak–Higashi syndrome, genetic defect unknown 15 0·20
Partial albinism and immunodeficiency syndrome 2 0·03
Other phagocytic disorders 15 0·20
Complement deficiencies 151 2·03
Hereditary angioedema (C1inh) 81 1·09
Complement component 2 deficiency 20 0·27
Mannose-binding lectin deficiency (MBL) 18 0·24
Other complement deficiencies 32 0·43
Other well-defined PIDs 1292 17·39
DNA-breakage disorders 510 6·86
Ataxia telangiectasia (ATM) 405 5·45
Nijmegen breakage syndrome (NBS1) 74 1·00
Fanconi anaemia 15 0·20
Other DNA-breakage disorders 16 0·22
DiGeorge syndrome 247 3·32
Wiskott–Aldrich syndrome (WAS) 289 3·89
Mutations in WASP 217 2·92
X-linked thrombocytopenia with mutations in WASP 2 0·03
Genetic defect unknown 70 0·94
X-linked lymphoproliferative syndrome (XLP) 37 0·50
X-linked (SH2D1A) 18 0·24
Genetic defect unknown 19 0·26
Hyper-IgE syndromes 120 1·62
Mutations in STAT3 15 0·20
Genetic defect unknown 105 1·41
Chronic mucocutaneous candidiasis (CMC) 26 0·35
Autoimmune polyendocrinopathy syndrome type I (AIRE) 2 0·03
Other CMC 24 0·32
Osteopetrosis 13 0·17
Asplenia syndrome 1 0·01
Cartilage hair hypoplasia 14 0·19
Defects of TLR/NFkappa-B signalling 11 0·15
Fc receptor deficiencies 2 0·03
Hermansky–Pudlak syndrome 3 2 0·03
Hoyeraal–Hreidarsson syndrome 8 0·11
Immunodeficiency centromeric instability facial anomalies syndrome (ICF) 9 0·12
Netherton syndrome 1 0·01
Schimke disease 2 0·03
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as the attending centre that entered the patient’s data. Euro-
pean health policies allow that patients may be seen in
centres outside their country of residence, which explains the
difference between the total number of patients documented
by centres in a given country and the number of patients
living in this country.
Analysis of data and studies
The ESID database offers a platform for different types of
studies on primary immunodeficiencies. European research-
ers have the opportunity to learn from other patients with a
specific diagnosis throughout Europe and can contact
appropriate documenting centres. The database has been
constructed so that users can access data on patients auto-
matically from their centre only. From the beginning of
2007, ESID offers a reporting tool which enables users to
query and analyse their centre’s data in more detail
themselves.
The ESID database has already been used in surveys on
X-linked thrombocytopenia (XLT) patients and neuroendo-
crine carcinoma in patients with CD40L deficiency. Multi-
centre clinical trials on common variable immunodeficiency
(CVID) and X-linked agammaglobulinaemia (XLA) are cur-
rently under way.
Results
The total number of registered patients was 7430 (November
2008). Of these cases, 6706 patients were alive, while 724
were deceased or lost to follow-up; 4312 patients (58%) had
one or more follow-up documentations in addition to the
initial registration.
Of all patients, 2911 (39·2%) were female and 4519
(60·8%) were male. We see a similar gender distribution both
among children and adults. Among the 6706 living patients,
3575 were aged 15 years or younger and 3131 patients were
aged 16 years or older. In the first group (15 years or younger),
2309 (64·6%) were male while 1266 (35·4%) were female.
Compared to this gender distribution, the female share was
slightly higher in the second group (aged 16 years or older):
1776 (56·7%) were male and 1355 (43·3%) were female.
Predominantly antibody deficiencies formed the largest
PID group with 4073 patients (54·8%), while CVID was by
far the most common single disease with 1540 patients
entered (20·7%) (Table 1).
Epidemiology
Using the number of documented patients, a minimum
prevalence of PID in the current total population can be
calculated for each participating country. As shown in
Table 2, this number is relatively low in many countries,
compared to results of earlier registries. This is due to the
fact that in most countries documentation is far from
complete. However, with 2804 registered patients, France
serves as the best example of a good coverage of PID
patients. Therefore, we have calculated the minimal inci-
dence of PID in newborns for France from 1995 to 2006,
grouped into 4-year periods (Fig. 1a).
The distribution of the PID categories shows that pre-
dominantly antibody disorders were the most common PID
in newborns. However, they were followed closely by phago-
cytic disorders and other well-defined PIDs. An analysis of
the data from the United Kingdom, where 907 patients have
Table 1. Continued
PID entity Total % of total
Autoimmune and immunedysregulation syndromes 98 1·32
Autoimmune lymphoproliferative syndrome (ALPS) 79 1·06
TNFRS member 6 deficiency (ALPS IA-type) 46 0·62
Other genetic defects 3 0·04
ALPS with unknown genetic cause 30 0·40
Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) 12 0·16
Immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) 7 0·09
Autoinflammatory syndromes 76 1·02
Familial mediterranean fever defect 60 0·81
TNF receptor-associated periodic syndrome (TRAPS) 10 0·13
Hyper-IgD syndrome (MVK) 5 0·07
CINCA syndrome 1 0·01
Unclassified immunodeficiencies 137 1·84
CINCA: chronic infantile neurological cutaneous articular syndrome; MVK: mevalonate kinase; TNF: tumour necrosis factor; TNFR: tumour
necrosis factor receptor; TLR: Toll-like receptor; NF: nuclear factor; STAT: signal transducer and activator of transcription 3; SBDS: Schwachman–
Bodan–Diamond syndrome; BTK: Bruton agammablobulinaemia tyrosine kinase; ICOS: inducible co-stimulatory molecule; HIGM: hyper-IgM;
CYBB: cytochromosome b588 b; WHIM: Wart, Hypogammaglobulinemia, Infection and Myelokathexis; NCF1: neutrophil cytosolic factor 1;
HLA: human leucocyte antigen.
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been registered, gives us a similar picture, although phago-
cytic disorders were recorded much less frequently (Fig. 1b).
To reach a better understanding of these numbers, we
must also take into account that many PID patients are diag-
nosed only after they have reached adulthood. For example,
in the ESID database, more than 21% of all registered
patients were diagnosed at 16 years of age or later. The share
is even greater in antibody disorders, where 33·9% were diag-
nosed in adulthood (Table 3).
Therefore, when looking at the time-span we selected to
calculate incidences (1995–2006), we must assume that at
least a fifth of the PID patients born in these years have not
yet been diagnosed, which means that both the total inci-
dence as well as the incidence for specific categories is actu-
ally higher than shown in Fig. 1. In particular, the incidence
rate for PID with a large share of late-onset and late-
diagnosis patients such as antibody disorders and comple-
ment deficiencies is probably remarkably higher.
Mortality
Data were evaluated for 641 deceased patients with informa-
tion available on the date of death. Life expectancy varies
considerably between the types of PID. While the oldest
antibody-deficient patient documented so far had lived as
long as 85 years, other PID categories show much lower
average ages at death (Fig. 2). However, with improved diag-
nosis and treatment, life expectancy for PID patients has
increased. For example, of 290 living patients with chronic
granulomatous disease (CGD), 24 were currently 30 years
and older. In contrast, among the deceased CGD patients,
the oldest had reached an age of only 27 years.
Therapy
Ig replacement represents one of the mainstay therapeutic
regimens in PID. Of the 6706 alive patients, 2819 (42%) were
receiving Ig replacement. Antibiotics were the second most
frequent drugs prescribed, and were taken on a regular basis
by 1516 patients (22·6%); 1410 patients (21%) were cur-
rently not receiving any permanent medication. A total of
632 patients (8·5% of all patients) had undergone bone
marrow transplantation.
The rate of Ig replacement was highest in the group of
antibody-deficient patients, where 2273 (57·4%) of 3960
living patients received this form of therapy. There was a
high rate of Ig replacement (1257 of 1479; 85%) in CVID
Table 2. Minimum primary immunodeficiency (PID) prevalence based
on reported cases in the European Society for Immunodeficiencies
(ESID) database: patients per 100 000 inhabitants by countries. Only
countries with a prevalence >0·2 are displayed.
Country
Alive PID
patients
documented
Population
(millions
inhabitants)
Documented
PID patients
per 100 000
inhabitants
France 2399 64·47 3·72
Ireland 76 4·24 1·79
Turkey 1083 70·59 1·53
United Kingdom 878 60·59 1·45
Estonia 15 1·34 1·12
Italy 655 59·13 1·11
Belgium 98 10·53 0·93
Poland 352 38·12 0·92
Czech Republic 88 10·31 0·85
Greece 89 11·17 0·8
Germany 552 82·24 0·67
Serbia 47 7·27 0·65
Switzerland 38 7·59 0·5
Slovakia 22 5·43 0·41
Sweden 32 9·18 0·35
Slovenia 6 2·02 0·3
Portugal 27 10·95 0·25
Total populations source: Wikipedia.
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Fig. 1. Minimum incidence of primary immunodeficiency (PID)
cases in 100 000 live births, grouped in 4-year periods, and
distribution in main PID categories. (a) France: n
(1995–2006) = 1110, demographics: INSEE (www.insee.fr); (b) United
Kingdom, n (1995–2006) = 288, demographics: UK Office for
National Statistics (www.statistics.gov.uk).
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patients and 382 of 415 (92%) XLA patients on Ig replace-
ment (Table 4).
Immunoglobulins were administered intravenously
(IVIG) in 2137 patients (75·8%), while 674 patients (23·9%)
made use of home therapy with subcutaneous Ig infusions
(SCIG) and two patients received intramuscular immunoglo-
bulins. In the remaining six patients, the route of application
was not documented.
The use of SCIG as home therapy is available in only some
European countries. Figure 3 shows that among the docu-
mented patients, Germany showed the highest rate of SCIG,
with 53·9% receiving SCIG and 46·1% receiving IVIG.
There are also differences in the mean interval of IVIG
administration between countries. However, the results
suggest that applying IVIG every 3–4 weeks is common in
many countries (Fig. 4).
A key target in Ig replacement is achieving an adequate
IgG trough level in the patient’s blood. The trough serum
level, which is measured immediately before Ig is adminis-
tered, should be at least 5 g/l, and ideally within the normal
range of healthy individuals (7–16 g/l) [10,11]. The mean
IgG trough level in the ESID database was 6·85 g/l for CVID
patients (720 patients receiving Ig replacement with infor-
mation on the trough level available) and 7 g/l for XLA
patients (178 patients).
Discussion
Our evaluations show that the documentation progress in
the ESID online database has gained momentum. While the
average number of newly reported cases per year was 954 in
October 2006, the time of our first publication, the average
increase since then has more than doubled to 2000 patients
per year, resulting in a total of 7430 documented patients.
However, documentation still lags behind in many coun-
tries, and there is a bias in the documentation due to the
limited number of institutions that document patients. For
example, complement deficiencies have risen from 0·6% to
2% of all cases since 2006, but this is still far from the 6%
share they had in the old ESID registry (1994–2002).
Table 3. Number of patients diagnosed in childhood and adulthood, by primary immunodeficiency (PID) category.
Main PID category
Patients diagnosed
by age 15 or younger
Patients diagnosed
by age 16 or older
Share of diagnosis
in adulthood (%)
All categories 5607 1533 21·47
Predominantly antibody disorders 2594 1332 33·93
Predominantly T cell deficiencies 643 17 2·58
Phagocytic disorders 852 29 3·29
Other well-defined PIDs 1185 62 4·97
Complement deficiencies 89 43 32·58
Autoinflammatory syndromes 67 9 11·84
Autoimmune and immunedysregulation syndromes 89 6 6·32
Unclassified immunodeficiencies 88 35 28·46
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Fig. 2. Age at death of patients from selected subcategories and
diseases. Box and whisker chart with whiskers representing the
maximum and minimum values; the box represents the upper and
lower quartile, the white line represents the median. The number of
evaluated patients is given in brackets.
0% 10%20%30%40%50%60%70%80%90%100
%
Russia (51)
Turkey (149)
Italy (452)
Ireland (33)
Poland (86)
Czech Republic (31)
Greece (38)
France (995)
Belgium (51)
United Kingdom (503)
Germany (330)
IVIG SCIG
Fig. 3. Shares of intravenous immunoglobulin (IVIG) and
subcutaneous immunoglobulin (SCIG) replacement in selected
European countries as documented in the European Society for
Immunodeficiencies (ESID) database. The total number of
documented patients receiving immunoglobulin replacement in each
country is given in brackets.
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Documentation has proved most successful in countries
with a national PID network that draws on local funds for
documentation. This is very notably the case in France,
where the national centre CEREDIH (www.ceredih.fr)
has already registered 2821 PID patients nationwide by
employing data entry personnel who travel to local hospi-
tals to document patient data. Several countries, such as
Germany, Switzerland, the United Kingdom and Sweden,
are currently in the process of setting up similar networks
with the aim of achieving, ideally, a complete nationwide
documentation.
It is relatively problematic to obtain valid data on the
epidemiology of PID. From our data set, we were able to
calculate a minimum prevalence which is merely an indica-
tor of how good is the documentation in each country.
However, with 2399 living patients documented in the het-
erogeneous population of France, the overall prevalence of
PID will not be less than 3·72 per 100 000.
Furthermore, it would be interesting to apply the very
promising approach which the Australasian Society for
Clinical Immunology and Allergy (ASCIA) has undertaken
recently to estimate PID morbidity [4]. Data on the
number of patients receiving Ig replacement for the indi-
cation of PID from national health authorities was used to
approximate the rate of under-reporting. The United
Kingdom is currently undertaking efforts to acquire similar
statistical data.
The ESID online database represents an outstanding
achievement, which was realized with limited financial
resources and thanks to the active contributions from PID
clinical teams and researchers. In view of the current
achievements, we are confident that the database is becom-
ing a valuable source for the management of and the research
on PID in all European countries.
Table 4. Percentage of alive patients receiving immunglobulin replacement within the largest primary immunodeficiency (PID) subgroups in the
European Society for Immunodeficiencies (ESID) database.
PID subcategory Alive patients
% receiving
immunoglobulin
(Ig) replacement (%)
Agammaglobulinaemias 494 91
Common variable immunodeficiency (CVID) 1479 85
Class switch recombination defects (CSR)/HIGM syndromes 215 57
X-linked lymphoproliferative syndrome (XLP) 33 51
Other unclassified T cell disorders 91 46
T–B- severe combined immunodeficiency (SCID) 138 45
HLA class II deficiency 32 43
Wiskott–Aldrich syndrome (WAS) 234 43
T–B+ severe combined immunodeficiency (SCID) 153 40
CD4-deficiency 35 31
Chronic mucocutaneous candidiasis (CMC) 26 30
Immunodeficiencies of unknown cause 129 25
Hypogammaglobulinaemias (without CVID) 1772 24
Hyper-IgE syndromes 112 23
DNA-breakage disorder 351 22
Familial haemophagocytic lymphohistiocytosis syndromes (FLH) 51 17
Autoimmune lymphoproliferative syndrome (ALPS) 73 15
Leucocyte adhesion deficiency (LAD) 28 7
Kostmann syndrome 61 6
Chronic granulomatous disease (CGD) 290 3
DiGeorge syndrome 227 3
Severe congenital neutropenia (cyclic and non-cyclic) 198 3
HIGM: hyper-IgM; HLA: human leucocyte antigen.
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Fig. 4. Mean interval of intravenous immunoglobulin (IVIG)
replacement by countries as documented in the European Society for
Immunodeficiencies (ESID) database. The total number of patients
currently treated with IVIG for whom the interval has been
documented is given in brackets. Only countries with 10 or more
cases containing data on intervals are displayed.
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